Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

UCB Lda.

NIF 500291322
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €35,237,239 42 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €35,237,239 42 contracts
A2 · Late Publication €6,222,013,796 903 contracts
Contract published to BASE more than 10 days after the signing date
LOW €6,222,013,796 903 contracts
A5 · Threshold Splitting €1,021,781 21 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €1,021,781 21 contracts
A6 · Low Competition €32,975,963 8 contracts
Only one bidder participated in a competitive procedure
MEDIUM €32,975,963 8 contracts
A9 · Abnormal Price Reduction €7,183,071,421 520 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €7,183,071,421 520 contracts
C3 · Missing Mandatory Fields €1,226,098 22 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €1,226,098 22 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

23
€431,647,791
25
€343,820,677
29
€339,740,308
19
€324,038,322
41
€303,446,712
94
€295,242,765
15
€285,257,849
20
€275,855,257
13
€273,557,095
63
€271,893,362
53
€271,546,395
14
€271,338,202
24
€271,282,168
100
€270,180,871
9
€267,762,843
9
€266,787,239
16
€264,373,433
15
€260,610,368
24
€239,789,124
83
€237,816,326
Page 1 of 4 · 63 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 1 · 21 contracts

Aquisição de Medicamentos Diversos, ao abrigo do AQ 2023-671, para a ULSASI, para o ano de 2025
PT · 11853466 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€4,916 2025-10-28
050100582025 - 1222/2024 - Aquisição ao Abrigo de vários Acordos- Quadro no âmbito da Agregação centralizada de medicamentos para o ano de 2025
PT · 11774544 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€19,674 2024-12-19
AQUISIÇÃO DE LACOSAMIDA 200 MG INJ
PT · 10821506 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€74,830 2024-07-16
PQ/1911/2024- LACOSAMIDA 10MG/ML INJ 20ML IV
PT · 10755402 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€72,038 2024-06-03
Aquisição de LACOSAMIDA IV 10MGML 20 ML SOL INJ ao Lab. UCB para o HFF para o ano de 2023
PT · 10773739 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,972 2023-10-26
MEDICAMENTOS
PT · 10295181 · Ajuste Direto Regime G...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€73,656 2023-10-11
Medicamentos do sn cerebrospinal exceto anestésicos, relaxantes musculares, analgésicos, antipiréticos, antidepressivos e anti psicóticos para o ano de 2022
PT · 10095979 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€144,023 2022-08-16
BEAD20220063 - IMUNOMODULADORES (EXCLUSIVOS) 2022 (CATALOGO - 1º SEMESTRE)
PT · 9196525 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€74,403 2022-03-24
Aquisição de Medicamentos do Sistema Nervoso
PT · 7813234 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€72,470 2021-06-22
AQUISIÇÃO DE MEDICAMENTOS DIVERSOS - 61/2019
PT · 7405320 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€73,239 2021-01-22
Diversos Medicamentos
PT · 6216741 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€19,524 2020-01-10
4180063/2019 - CERTOLIZUMAB 200 MG - AQ. CENTRALIZADA SPMS
PT · 5821871 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€73,681 2019-01-10
MEDICAMENTOS
PT · 4919199 · Ajuste Direto Regime G...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€19,704 2018-10-25
FI0307/2018 - CERTOLIZUMAB PEGOL 200 MG (200MG/ML SER 1 ML) SOL INJ
PT · 5461886 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€4,963 2018-04-24
FI0288/2018 - CERTOLIZUMAB PEGOL 200 MG (200MG/ML SER 1 ML) SOL INJ
PT · 5431988 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€4,963 2018-04-09
Q1/13/2018 MEDICAMENTOS DIVERSOS
PT · 4467526 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€145,227 2018-03-07
Lacosamidas - CPA 2017/2
PT · 4881867 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€4,800 2018-03-05
FI0243/2017- CERTOLizumab PEGOL 200 MG (200MG/ML SER 1 ML) SOL INJ
PT · 3585069 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€4,963 2017-03-07
CERTOLIZUMAB 200MG/ML SERINGA PRÉ-CHEIA
PT · 2886801 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,868 2016-12-12
AQUISIÇÃO DE CERTOLIZUMAB 200MG/ML SERINGA PRÉ-CHEIA
PT · 2342771 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,868 2016-08-05
AD/140/2013 - Aquisição de Medicamentos Diversos
PT · 841765 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award +1
€74,999 2013-09-30
Overview
Total Value Won
€7,199,871,269
Contracts Won
1,206
Score 44755 · CRITICAL RISK
NIF
500291322
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • F.J. [P-5790]
    Gerente
    since 2016-07-29
  • P.F. [P-0038]
    Gerente
    since 2019-12-20
  • U.F. [P-d7f3]
    Sócio
    since 2012-01-17
  • U.F. [P-d7f3]
    Sócio
    since 2018-03-21
  • U.S. [P-356b]
    Sócio
    since 2018-03-21
  • V.P. [P-f824]
    Sócio
    since 2012-01-17
  • A.J. [P-1ffd]
    Gerente
    2010-03-12 → 2012-05-29
  • J.A. [P-e101]
    Gerente
    until 2010-03-12
  • J.M. [P-56a4]
    Gerente
    2012-05-29 → 2019-12-20
  • J.C. [P-3ee9]
    Gerente
    2013-06-20 → 2016-07-29
  • M.L. [P-9402]
    Gerente
    2012-03-28 → 2013-06-20
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned